Difference between revisions of "Part:BBa K1722000"
 
(56 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
__NOTOC__
 
__NOTOC__
 +
<html>
 +
<img style="width:10%" src="https://static.igem.org/mediawiki/2015/2/2c/SZU_China_igem_logo.png"/
 +
</html>
 +
{| style="color:black" cellpadding="5" cellspacing="1" border="3" align="right"
 +
! colspan="2" style="background:#d7474e;"|hUPll
 +
|-
 +
|'''Function'''
 +
|Promoter
 +
|-
 +
|'''Use in'''
 +
|Bladder cells
 +
|-
 +
|'''RFC standard'''
 +
|[https://parts.igem.org/Help:Assembly_standard_10 RFC 10]
 +
|-
 +
|'''Backbone'''
 +
|[https://parts.igem.org/Help:Plasmid_Backbones pSB1C3]
 +
|-
 +
|'''Submitted by'''
 +
|[http://2015.igem.org/Team:SZU_China SZU_China 2015]
 +
|}
 +
=====<partinfo>BBa_K1722000 short</partinfo>=====
 +
hUPll is a bladder tissue-specific promoter being found in human urothelium. Uroplakin II (UPII) has been characterized as a bladder tissue-specific protein<sup>[1]</sup> and the expression of uroplakin II was found to be limited to bladder-derived cells.<sup>[2,3]</sup> Other members of uroplakins, including uroplakinla(UPla), uroplakinlb(UPlb), and uroplakinlll(UPlll), have also been characterized. Therefore, the promoters that direct the expression of the uroplakins may be useful in constructing tissue-specific vectors for bladder cancer gene therapy. Research shows that most of the elements that confer the bladder-specificity and differentiation-dependent expression of the human UPll gene reside in the 2542-bp sequence, and TNF driven by the human UPll(hUPll) promoter is effective in the specific inhibition of bladder cancer growth both in vivo and in vitro. Zhu et al transtected the plasmid phUPll-EGFP containing DNA fragment(hUPll) into bladder cancer(BIU-87), renal carcinoma(GRC-1) and endothelial(EC) cell lines.<sup>[4]</sup>(<b>Fig. 1</b>)
  
 +
<html>
  
 +
<figure style="text-align: center"><img style="width:100%" src="https://static.igem.org/mediawiki/2015/3/38/HUPll_GFP_figure.png"/><figcaption style="text-align:left"><b>Figure 1.</b> The plasmid phUPII-EGFP containing DNA fragment (hUPII) 2542 bp upstream of the UPII gene was transfected into bladder cancer (BIU-87), renal carcinoma (GRC-1), and endothelial (EC) cell lines. Transient transfection was determined either by confocal microscopy or flow cytometric analysis of GFP expression.  <b>(a)</b>The activity of human UPII promoter in BIU-87, GRC-1, and EC cell lines. Positive green signals from UPII were more and stronger in BIU-87 than in EC and GRC-1 cell lines.<b>(b)</b> The GFP activity in BIU-87, GRC-1, and EC was tested by flow cytometry. A positive rate from UPII was higher in BIU-87 than in EC and GRC-1 cell lines. The percentage of GFP-positive cells in BIU-87 cell line, EC cell line, and GRC-1 cell line was 10.1, 1.8, and 0% respectively.<sup>[4]</sup></figcaption></figure>
  
−
<partinfo>BBa_K1722000 short</partinfo>
+
</html>
  
−
hUPll is a bladder tissue-specific promoter being found in human urothelium. Uroplakin II (UPII) has been characterized as a bladder tissue-specific protein<sup>[1]</sup> and the expression of uroplakin II was found to be limited to bladder-derived cells.<sup>[2,3]</sup> Other members of uroplakins, including uroplakinla(UPla), uroplakinlb(UPlb), and uroplakinlll(UPlll), have also been characterized. Therefore, the promoters that direct the expression of the uroplakins may be useful in constructing tissue-specific vectors for bladder cancer gene therapy. Research shows that most of thecis elements that confer the bladder-specificity and differentiation-dependent expression of the human UPll gene reside in the 2542-bp sequence, and TNF driven by the human UPll(hUPll) promoter is effective in the specific inhibition of bladder cancer growth both in vivo and in vitro.  
+
hUPll is 355bp in length. <b>Fig. 2</b> shows the DNA sequence of hUPll is successfully amplified by PCR from psi-Check2 vector. From this electrophoretogram, we can see the brightness of hUPll PCR product is rather high compared with DNA Marker, which indicates that the PCR product of hUPll is in a high concerntration.
 +
<html>
 +
<figure style="text-align: center"><img style="width:30%" src="https://static.igem.org/mediawiki/2015/2/26/HUPll_pcr2.png"/><figcaption style="text-align:center"><b>Figure 2.</b> Electrophoretic analysis of PCR produution of hUPll promoter from psi-Check2. (1:PCR production 2:DL2000 DNA Marker)</figcaption></figure>
  
 +
</html>
 +
 +
After ligating hUPll and pSB1C3, we transfected the new pasmid being constructed into Ecoli and selected those Ecoli with Chl resistence. Using these Ecoli as templet, we amplified hUPll from pSB1C3,<b>(Fig. 3)</b> which means we had successfly construacted the pSB1C3-hUPll plasmid.
 +
<html>
 +
 +
<figure style="text-align: center"><img style="width:50%" src="https://static.igem.org/mediawiki/2015/7/71/HUPll_pcr%E9%AA%8C%E8%AF%81.png"/><figcaption style="text-align:center"><b>Figure 3.</b> Electrophoretic analysis of PCR product of hUPll promoter from pSB1C3. (1:DL2000 DNA Marker 2,3,4:PCR product)</figcaption></figure>
 +
 +
</html>
 +
 +
We then performed single digest(EcoRI) and double digest(EcoRI & PstI) to identify our pSB1C3-hUPll plasmid. From the eletrophoretogram, we have an electrophoresis strip at about 2425bp in Track 1 and two strips at about 355bp, which is exactly the length of hUPll promoter and 2070bp, which is the length of pSB1C3 in Track 2. From this enzyme cutting result, we could make sure the Gene sequence of hUPll succeeded in being constructed into pSB1C3 vector.
 
<html>
 
<html>
  
−
<figure style="text-align: center">[[File:HUPll_GFP.png]]<figcaption style="text-align:left"><b>Figure 1.</b> The plasmid phUPII-EGFP containing DNA fragment (hUPII) 2542 bp upstream of the UPII gene was transfected into bladder cancer (BIU-87), renal carcinoma (GRC-1), and endothelial (EC) cell lines. Transient transfection was determined either by confocal microscopy or flow cytometric analysis of GFP expression.  <b>(a)</b>The activity of human UPII promoter in BIU-87, GRC-1, and EC cell lines. Positive green signals from UPII were more and stronger in BIU-87 than in EC and GRC-1 cell lines.<b>(b)</b> The GFP activity in BIU-87, GRC-1, and EC was tested by flow cytometry. A positive rate from UPII was higher in BIU-87 than in EC and GRC-1 cell lines. The percentage of GFP-positive cells in BIU-87 cell line, EC cell line, and GRC-1 cell line was 10.1, 1.8, and 0% respectively. </figcaption></figure>
+
<figure style="text-align: center"><img style="width:30%" src="https://static.igem.org/mediawiki/2015/a/a6/HUPll_%E5%8D%95%E5%8F%8C%E9%85%B6%E5%88%87.png"/><figcaption style="text-align:center"><b>Figure 4.</b> Identification of recombinant plasmids pSB1C3-hUPll by one and two restriction enzymes. [1:pSB1C3-hUPll single digest(EcoRI) 2:pSB1C3-hUPll double digest(EcoRI and PstI) 3:DL2000 DNA Marker]</figcaption></figure>
  
 +
</html>
  
 
2015 SZU-iGEM use hUPII to drive the expression of the therapeutic genes(such as p21 and Bax) so that the gene is expressed only in bladder cells and systematic toxicity is minimized. We tested hUPII promoter in HFC(Human Fiber Epithelial Cells)，5637，T24 and Hela cell lines. HFC are normal bladder cells, 5637 and T24 are bladder cancer cells while Hela are cervical cancer cells. Result shows it can confer preferential expression of genes in the bladder urothelium like HFC, 5637 and T24, which indicates hUPll has high efficiency in specifically recognizing bladder cells.
 
2015 SZU-iGEM use hUPII to drive the expression of the therapeutic genes(such as p21 and Bax) so that the gene is expressed only in bladder cells and systematic toxicity is minimized. We tested hUPII promoter in HFC(Human Fiber Epithelial Cells)，5637，T24 and Hela cell lines. HFC are normal bladder cells, 5637 and T24 are bladder cancer cells while Hela are cervical cancer cells. Result shows it can confer preferential expression of genes in the bladder urothelium like HFC, 5637 and T24, which indicates hUPll has high efficiency in specifically recognizing bladder cells.
Line 21: Line 59:
 
<partinfo>BBa_K1722000 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K1722000 SequenceAndFeatures</partinfo>
  
−
 
+
==='''Design Notes'''===
−
===Design Notes===
+
 
We designed the following primers and amplified hUPII promoter from the vector psi-Check2:
 
We designed the following primers and amplified hUPII promoter from the vector psi-Check2:
  
Line 31: Line 68:
  
  
−
===Source===
+
==='''Source'''===
  
 
hUPII gene was achieved from Shenzhen Second People's Hospital. We read a scientific treatise talking about targeted therapy of bladder cancer written by a doctor in Shenzhen Second People's Hospital and tried to seek cooperation with them. Fortunately, they agree to provide us hUPII with psi-Check2 as its vector.
 
hUPII gene was achieved from Shenzhen Second People's Hospital. We read a scientific treatise talking about targeted therapy of bladder cancer written by a doctor in Shenzhen Second People's Hospital and tried to seek cooperation with them. Fortunately, they agree to provide us hUPII with psi-Check2 as its vector.
  
−
<html>
+
  
−
===References===
+
==='''References'''===
  
 
[1]Wu XR, Lin JH, Walz T, et al. Mammalian uroplakins, a group of highly conserved urothelial differentiation related membrane    proteins. J Biol Chem. 1994;269:13716–13724.
 
[1]Wu XR, Lin JH, Walz T, et al. Mammalian uroplakins, a group of highly conserved urothelial differentiation related membrane    proteins. J Biol Chem. 1994;269:13716–13724.
Line 46: Line 83:
 
membrane proteins of urothelial umbrella cells as histological markers of metastatic transitional cell carcinomas. Am
 
membrane proteins of urothelial umbrella cells as histological markers of metastatic transitional cell carcinomas. Am
 
J Pathol. 1995;147:1383–1397.
 
J Pathol. 1995;147:1383–1397.
 +
 +
[4]Zhu H J, Zhang ZQ, Zeng XF, et al. Cloning and analysis of human uroplakin II promoter and its ap plication for gene
 +
therapy in bladder cancer[J] Cancer Gene Ther, 2004, 11: 263-272
  
  

Latest revision as of 14:14, 17 September 2015

hUPll
Function Promoter
Use in Bladder cells
RFC standard RFC 10
Backbone pSB1C3
Submitted by [http://2015.igem.org/Team:SZU_China SZU_China 2015]
hUPll is a bladder tissue-specific promoter .

hUPll is a bladder tissue-specific promoter being found in human urothelium. Uroplakin II (UPII) has been characterized as a bladder tissue-specific protein[1] and the expression of uroplakin II was found to be limited to bladder-derived cells.[2,3] Other members of uroplakins, including uroplakinla(UPla), uroplakinlb(UPlb), and uroplakinlll(UPlll), have also been characterized. Therefore, the promoters that direct the expression of the uroplakins may be useful in constructing tissue-specific vectors for bladder cancer gene therapy. Research shows that most of the elements that confer the bladder-specificity and differentiation-dependent expression of the human UPll gene reside in the 2542-bp sequence, and TNF driven by the human UPll(hUPll) promoter is effective in the specific inhibition of bladder cancer growth both in vivo and in vitro. Zhu et al transtected the plasmid phUPll-EGFP containing DNA fragment(hUPll) into bladder cancer(BIU-87), renal carcinoma(GRC-1) and endothelial(EC) cell lines.[4](Fig. 1)

Figure 1. The plasmid phUPII-EGFP containing DNA fragment (hUPII) 2542 bp upstream of the UPII gene was transfected into bladder cancer (BIU-87), renal carcinoma (GRC-1), and endothelial (EC) cell lines. Transient transfection was determined either by confocal microscopy or flow cytometric analysis of GFP expression. (a)The activity of human UPII promoter in BIU-87, GRC-1, and EC cell lines. Positive green signals from UPII were more and stronger in BIU-87 than in EC and GRC-1 cell lines.(b) The GFP activity in BIU-87, GRC-1, and EC was tested by flow cytometry. A positive rate from UPII was higher in BIU-87 than in EC and GRC-1 cell lines. The percentage of GFP-positive cells in BIU-87 cell line, EC cell line, and GRC-1 cell line was 10.1, 1.8, and 0% respectively.[4]

hUPll is 355bp in length. Fig. 2 shows the DNA sequence of hUPll is successfully amplified by PCR from psi-Check2 vector. From this electrophoretogram, we can see the brightness of hUPll PCR product is rather high compared with DNA Marker, which indicates that the PCR product of hUPll is in a high concerntration.

Figure 2. Electrophoretic analysis of PCR produution of hUPll promoter from psi-Check2. (1:PCR production 2:DL2000 DNA Marker)

After ligating hUPll and pSB1C3, we transfected the new pasmid being constructed into Ecoli and selected those Ecoli with Chl resistence. Using these Ecoli as templet, we amplified hUPll from pSB1C3,(Fig. 3) which means we had successfly construacted the pSB1C3-hUPll plasmid.

Figure 3. Electrophoretic analysis of PCR product of hUPll promoter from pSB1C3. (1:DL2000 DNA Marker 2,3,4:PCR product)

We then performed single digest(EcoRI) and double digest(EcoRI & PstI) to identify our pSB1C3-hUPll plasmid. From the eletrophoretogram, we have an electrophoresis strip at about 2425bp in Track 1 and two strips at about 355bp, which is exactly the length of hUPll promoter and 2070bp, which is the length of pSB1C3 in Track 2. From this enzyme cutting result, we could make sure the Gene sequence of hUPll succeeded in being constructed into pSB1C3 vector.

Figure 4. Identification of recombinant plasmids pSB1C3-hUPll by one and two restriction enzymes. [1:pSB1C3-hUPll single digest(EcoRI) 2:pSB1C3-hUPll double digest(EcoRI and PstI) 3:DL2000 DNA Marker]

2015 SZU-iGEM use hUPII to drive the expression of the therapeutic genes(such as p21 and Bax) so that the gene is expressed only in bladder cells and systematic toxicity is minimized. We tested hUPII promoter in HFC(Human Fiber Epithelial Cells)，5637，T24 and Hela cell lines. HFC are normal bladder cells, 5637 and T24 are bladder cancer cells while Hela are cervical cancer cells. Result shows it can confer preferential expression of genes in the bladder urothelium like HFC, 5637 and T24, which indicates hUPll has high efficiency in specifically recognizing bladder cells.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Design Notes

We designed the following primers and amplified hUPII promoter from the vector psi-Check2:

CCGGAATTCATCGGGTGATCAGTACTCC(up) TGCACTGCAGACTAGTACTGAGCTGTGAGGT(down)

By incorporating these primers into hUPII promoter, the promoter is flanked by the iGEM prefix and suffix after amplification.


Source

hUPII gene was achieved from Shenzhen Second People's Hospital. We read a scientific treatise talking about targeted therapy of bladder cancer written by a doctor in Shenzhen Second People's Hospital and tried to seek cooperation with them. Fortunately, they agree to provide us hUPII with psi-Check2 as its vector.


References

[1]Wu XR, Lin JH, Walz T, et al. Mammalian uroplakins, a group of highly conserved urothelial differentiation related membrane proteins. J Biol Chem. 1994;269:13716–13724.

[2]Yuasa T, Yoshiki T, Isono T, et al. Expression of transitional cell specific genes uroplakin Ia and II in bladder cancer detection of circulating cancer cells in the peripheral blood of metastatic patients. Int J Urol. 1999;6:286–292.

[3]Moll R, Wu XR, Lin JH, Sun TT. Uroplakins specific membrane proteins of urothelial umbrella cells as histological markers of metastatic transitional cell carcinomas. Am J Pathol. 1995;147:1383–1397.

[4]Zhu H J, Zhang ZQ, Zeng XF, et al. Cloning and analysis of human uroplakin II promoter and its ap plication for gene therapy in bladder cancer[J] Cancer Gene Ther, 2004, 11: 263-272